The blockade of the interaction between the HLA-E and the NKG2A receptor is an important drug discovery target since it can unleash the anti-tumor immunity of cytotoxic NK and CD8+ T cells (Andre et al. 2018; Kamiya et al. 2019). The gene discussed is CD8A; the disease is neoplasm.